Search
indacaterol (Arcapta)
Indications:
- chronic obstructive pulmonary disease
- chronic bronchitis, pulmonary emphysema
Dosage:
- once daily maintenance inhaler
capsules for dry powder inhaler:
- 75 mcg indacaterol inhalation powder
- capsules must be used with the neohaler device
Adverse effects:
- black box warning: possible increased risk of asthma-related death
- cough (6-25%)
- oropharyngeal pain (2%)
- nasopharyngitis (5%)
- headache (5%)
- nausea (2%)
Drug interactions:
- consistent with those of other beta-2 adrenergic agonists
- concomitant use with MAO inhibitors, tricyclic antidepressants, & drugs that prolong the QTc interval may potentiate indacaterol's cardiovascular effects
Mechanism of action:
- long-acting beta-2 adrenergic agonist
- bronchodilator, relaxation of bronchial smooth muscle
Interactions
drug adverse effects of adrenergic receptor agonists
General
inhaled beta-2 adrenergic receptor agonist
References
- Wikipedia: Indacaterol
http://en.wikipedia.org/wiki/Indacaterol
- Brooks M
Medcape Oncology
FDA Panel Backs Lower Dose of Indacaterol Maleate for COPD
http://www.medscape.com/viewarticle/738653
- Prescriber's Letter 19(1): 2012
New Drug: Arcapta (Indacaterol)
Detail-Document#: 280104
(subscription needed) http://www.prescribersletter.com
Component-of
glycopyrrolate/indacaterol